Physician profile
Aba Somers
NPI 1245352319
$843.57
in general payments reported to CMS, 2019-2025
15 companies · $162 in 2025
The $162 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $325 · 2021: $21.75 · 2022: $88.25 · 2023: $85.88 · 2024: $161 · 2025: $162.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $408.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $408.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $138.49 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Janssen Pharmaceuticals, INC | $129.12 | 2023-2024 | Xarelto |
| Glaxosmithkline, LLC. | $95.94 | 2019-2023 | Nucala |
| Regeneron Healthcare Solutions, INC. | $93.49 | 2019-2025 | Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $89.05 | 2019 | |
| Amgen INC. | $61.40 | 2019 | |
| Genzyme Corporation | $51.69 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $43.62 | 2019 | |
| Inogen, INC. | $35.35 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $23.07 | 2019 | |
| Viatris Specialty LLC | $22.83 | 2025 | Yupelri |
| Pharmacyclics LLC, An Abbvie Company | $18.93 | 2019 | |
| Novartis Pharmaceuticals Corporation | $16.78 | 2022 | |
| Exelixis INC. | $12.85 | 2019 | |
| Circassia INC. | $10.96 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aba Somers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.